ArticleInternational journal of clinical and experimental medicine2015
Pharmacokinetic and bioavailability study of angeloylgomisin H in rat plasma by UPLC-MS/MS.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- The Effect of Single-Dose Ougan Juice Application on the Pharmacokinetics of Erlotinib.BioMed research international · 2021Article
- A Rapid UPLC-MS Method for Quantification of Gomisin D in Rat Plasma and Its Application to a Pharmacokinetic and Bioavailability Study.Molecules (Basel, Switzerland) · 2019Article
- Pharmacokinetic Study of Delavinone in Mice after Intravenous and Oral Administration by UPLC-MS/MS.BioMed research international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angeloylgomisin H, as a major lignin in the fruits, was reported to have the potential to improve insulin-stimulated glucose uptake by activating PPAR-γ. In this work, a sensitive and selective UPLC-MS/MS method for determination of angeloylgomisin H in rat plasma is developed. After addition of rutin as an internal standard (IS), protein precipitation by acetonitrile was used to prepare samples. Chromatographic separation was achieved on a UPLC BEH C18 column (2.1 mm × 100 mm, 1.7 μm) with 0.1% formic acid and acetonitrile as the mobile phase with gradient elution. An electrospray ionization source was applied and operated in positive ion mode; multiple reactions monitoring (MRM) mode was used for quantification using target fragment ions m/z 523.2-315.1 for angeloylgomisin H, and m/z 611.1-303.1 for IS. Calibration plots were linear throughout the range 5-2000 ng/mL for angeloylgomisin H in rat plasma. Mean recoveries of angeloylgomisin H in rat plasma ranged from 86.2% to 92.5%. RSD of intra-day and inter-day precision were both < 11%. The accuracy of the method was between 93.0% and 104.1%. The method was successfully applied to pharmacokinetic study of angeloylgomisin H after either oral or intravenous administration. The absolute bioavailability of angeloylgomisin H was reported as high as 4.9%.
Indexed as
Identifiers
26770391PMC4694291W2413907577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.